Physician profile
Erica E Hightower
NPI 1629198726
$34,405.95
in general payments reported to CMS, 2019-2025
65 companies · $2,606 in 2025
The $2,606 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,233 · 2020: $3,880 · 2021: $9,189 · 2022: $1,662 · 2023: $3,837 · 2024: $5,000 · 2025: $2,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,850 · Travel and Lodging: $1,407 · Gift: $119 · Education: $66.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,849.89 |
| Travel and Lodging | $1,407.28 |
| Gift | $118.80 |
| Education | $66.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $10,856.06 | 2019-2025 | |
| Mannkind Corporation | $5,470.87 | 2019-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $2,255.74 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $2,037.68 | 2022-2025 | Minimed 780g |
| Insulet Corporation | $1,496.36 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $1,264.42 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Dexcom, INC. | $1,200.22 | 2019-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $761.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $685.88 | 2019-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $676.04 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $612.69 | 2021-2025 | |
| Corcept Therapeutics | $448.89 | 2019-2025 | Korlym |
| Esperion Therapeutics, INC. | $397.56 | 2021-2025 | Nexletol, Nexlizet |
| Beta Bionics, INC. | $394.91 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astellas Pharma US INC | $369.28 | 2024-2025 | Veozah |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $347.84 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $310.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $295.87 | 2019-2021 | |
| Cequr Corporation | $265.34 | 2023-2025 | Cequr Simplicity |
| Companion Medical, INC. | $250.45 | 2019-2020 | |
| Abbott Laboratories | $243.90 | 2019-2025 | Freestyle Libre 3 |
| Intuity Medical INC | $236.87 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Abbvie INC. | $229.14 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $221.11 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $220.71 | 2019-2023 | |
| Sequel Med Tech, LLC | $175.78 | 2025 | Twiist |
| Radius Health, INC. | $164.44 | 2023-2025 | Tymlos |
| Zealand Pharma US, INC. | $158.27 | 2020-2021 | |
| Shire North American Group INC | $150.49 | 2019 | |
| Alnylam Pharmaceuticals INC. | $125.01 | 2024 | Amvuttra |
| Medtronic Minimed, INC. | $124.48 | 2019 | |
| Antares Pharma, INC. | $124.37 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Alexion Pharmaceuticals, INC. | $118.84 | 2020-2025 | Strensiq |
| Becton, Dickinson and Company | $118.21 | 2019-2021 | |
| Ibsa Pharma INC. | $115.81 | 2020-2024 | Licart, Tirosint, Tirosint |
| Madrigal Pharmaceuticals | $110.24 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.43 | 2019-2023 | Cycloset |
| Shield Therapeutics INC | $108.02 | 2023-2024 | Accrufer |
| Amneal Pharmaceuticals LLC | $95.26 | 2022-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $88.49 | 2023-2025 | Isturisa, Signifor Lar |
| Amphastar Pharmaceuticals, INC. | $84.08 | 2024-2025 | |
| Tolmar, INC. | $79.67 | 2023-2024 | |
| Horizon Therapeutics Plc | $69.84 | 2022-2023 | Tepezza |
| Amryt Pharma Holdings LTD | $58.42 | 2023 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $58.35 | 2025 | Yorvipath |
| Arbor Pharmaceuticals, INC. | $53.48 | 2019-2021 | |
| Halozyme INC | $50.97 | 2023 | |
| Alvogen INC | $46.44 | 2022-2025 | Teriparatide |
| Kyowa Kirin, INC. | $44.60 | 2024-2025 | Crysvita |
| Currax Pharmaceuticals LLC | $42.35 | 2020-2021 | |
| Avvisto Therapeutics, LLC | $40.63 | 2025 | Cycloset |
| Nevro Corp. | $39.10 | 2022-2023 | Senza |
| Senseonics, Incorporated | $33.00 | 2019-2020 | |
| Sandoz INC. | $30.80 | 2024 | |
| Vivus LLC | $30.60 | 2019-2020 | |
| Bigfoot Biomedical INC | $29.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.89 | 2024 | |
| Boston Scientific Corporation | $24.28 | 2021 | |
| Grt US Holding, INC. | $22.92 | 2022 | |
| Averitas Pharma INC. | $21.55 | 2023 | Qutenza |
| Azurity Pharmaceuticals, INC. | $19.96 | 2024 | Azmiro |
| Pfizer INC. | $17.97 | 2024 | |
| Acella Pharmaceuticals, LLC | $16.11 | 2025 | NP Thyroid 60 |
| Medtronic Vascular, INC. | $15.90 | 2019 | |
| Intra-Sana Laboratories | $14.89 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Hightower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.